Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
Sylvia Adams(New York University), Sherene Loi(Peter MacCallum Cancer Centre), Deborah Toppmeyer(Rutgers, The State University of New Jersey), David W. Cescon(Princess Margaret Cancer Centre), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Rita Nanda(University of Chicago), Eric P. Winer(Dana-Farber Cancer Institute), Hirofumi Mukai(National Cancer Center Hospital East), Kenji Tamura, Anne Armstrong(The Christie NHS Foundation Trust), M.C. Liu(Mayo Clinic), Hiroji Iwata(Aichi Cancer Center), L Ryvo(Tel Aviv Sourasky Medical Center), Pauline Wimberger(University Hospital Carl Gustav Carus), Hope S. Rugo(UCSF Helen Diller Family Comprehensive Cancer Center), Antoinette R. Tan(Levine Cancer Institute), Lin Jia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yu Ding(Merck & Co., Inc., Rahway, NJ, USA (United States)), Vassiliki Karantza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter Schmid(Queen Mary University of London)
Cited by 625